SEC Form 10-Q filed by Rein Therapeutics Inc.
$RNTX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2025 | $8.00 | Buy | Rodman & Renshaw |
8-K - Rein Therapeutics, Inc. (0001420565) (Filer)
10-Q - Rein Therapeutics, Inc. (0001420565) (Filer)
8-K - Rein Therapeutics, Inc. (0001420565) (Filer)
Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00
AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Company to initiate its Phase 2 "RENEW" clinical trial of LTI-03, the Company's lead drug candidate for idiopathic pulmonary fibrosis (IPF). IPF is a serious, progressive lung disease that affects hundreds of thousands of people worldwide. It scars the lungs, leaving patients short of breath and with limited treatment options. Median
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that Chief Scientific Officer, Cory Hogaboam, and Chief Executive Officer, Brian Windsor, will each present at the IPF Summit 2025, taking place August 19-21, 2025, in Boston, MA. Dr. Hogaboam will present at 8:00 am on Tuesday in a workshop titled, "Decoding the Disruptions in Natural Biological Processes to Advance Early Intervention in IPF – Unravelling the Molecular Biology of Immune Cells & Inflammation." He will di
Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced a transformative strategic collaboration with DoveTree Medicines, a biotechnology pioneer founded by renowned drug developer Dr. Gregory Verdine. The collaboration, worth up to $5.99 billion, represents one of the largest commitments to date for AI- and robotics-driven pharmaceutical R&D.
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)